[{"id":"0005db66-97a2-46a0-8192-8f0061bcd96d","acronym":"KEYNOTE-A62","url":"https://clinicaltrials.gov/study/NCT04336098","created_at":"2021-01-18T20:59:34.166Z","updated_at":"2025-02-25T16:10:09.652Z","phase":"Phase 1","brief_title":"Study of SRF617 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04336098 - KEYNOTE-A62","lead_sponsor":"Coherus Biosciences, Inc.","biomarkers":" HER-2 • PD-L1","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • gemcitabine • albumin-bound paclitaxel • perenostobart (SRF617)"],"overall_status":"Completed","enrollment":" Enrollment 85","initiation":"Initiation: 03/16/2020","start_date":" 03/16/2020","primary_txt":" Primary completion: 08/25/2023","primary_completion_date":" 08/25/2023","study_txt":" Completion: 08/25/2023","study_completion_date":" 08/25/2023","last_update_posted":"2024-06-04"}]